Publikationen in Zusammenarbeit mit Forschern von Complexo Hospitalario Universitario de Santiago (27)

2024

  1. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

    Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096

  2. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

  3. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

    Haematologica, Vol. 109, Núm. 7, pp. 2219-2228

2023

  1. AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability

    Brain, Behavior, and Immunity, Vol. 108, pp. 255-268

2022

  1. A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research

  2. Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness

    Frontiers in Cell and Developmental Biology, Vol. 10

2021

  1. A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia

    Cancer, Vol. 127, Núm. 12, pp. 2003-2014

  2. Cancer epigenetic biomarkers in liquid biopsy for high incidence malignancies

    Cancers, Vol. 13, Núm. 12

  3. Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma

    Frontiers in Cell and Developmental Biology, Vol. 9

  4. Circulating levels of the interferon-γ-regulated chemokines cxcl10/cxcl11, il-6 and hgf predict outcome in metastatic renal cell carcinoma patients treated with antiangiogenic therapy

    Cancers, Vol. 13, Núm. 11

  5. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

    Leukemia, Vol. 35, Núm. 8, pp. 2358-2370

  6. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

    Blood Cancer Journal, Vol. 11, Núm. 5

  7. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 6, pp. 586-598

2020

  1. Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study

    Journal of Neuro-Oncology, Vol. 148, Núm. 3, pp. 545-554

2019

  1. Are there enough radiation oncologists to lead the new Spanish radiotherapy?

    Clinical and Translational Oncology, Vol. 21, Núm. 12, pp. 1663-1672

  2. Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib

    Oncotarget, Vol. 9, Núm. 97, pp. 36894-36905

  2. CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell-Relevant Genes

    Cancer Immunology Research, Vol. 6, Núm. 1, pp. 69-78

  3. Liquid Biopsy: From Basic Research to Clinical Practice

    Advances in Clinical Chemistry (Academic Press Inc.), pp. 73-119

2017

  1. Translating cancer epigenomics into the clinic: focus on lung cancer

    Translational Research, Vol. 189, pp. 76-92